Landmark survival analysis has been commonly applied before [46,47,48,49] to investigate non-baseline predictors, e.g., tumor dynamics, and avoids predicting events before the monitoring time of the predictor (i.e., prediction of PFS or OS before assessment of CRP at treatment cycle 3) [20]. Here, CRP is linked to neoplasm.